Tactile Systems

Tactile Systems Technology, Inc. is a medical technology company. It develops and provides innovative medical devices for the treatment of chronic diseases at home. The firm focus on advancing the standard of care in treating chronic diseases in the home setting to improve patient outcomes and quality of life and help control rising healthcare expenditures. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tactile Systems reports strong Q4 earnings, eyes growth and innovation

Tactile Systems delivered impressive Q4 2022 results with strong revenue growth, positive net income, and operational advancements, positioning the company for future success.
Strategic priorities for 2023 focus on sales team productivity, new product innovation, and operational efficiency, highlighting a commitment to sustained growth and market leadership.
Challenges include managing sales force turnover, supply chain constraints, and financial complexities post-2023, requiring proactive solutions and strategic decision-making.
Opportunities lie in capitalizing on revenue growth momentum, new product developments, and achieving an expanded adjusted EBITDA profile, signaling potential for continued success and value creation.

Tactile Systems reports robust Q1 growth, focuses on innovation

Tactile Systems delivered strong financial performance and operational advancements in Q1 2023, showcasing growth potential and a commitment to innovation and patient care.
While facing challenges in supply chain readiness and operational efficiency, the company's strategic focus on enhancing Medicare processes and product development presents opportunities for future success.
Overall, Tactile Systems' earnings call highlighted a positive trajectory with increased revenue guidance, product innovation, and a dedication to improving patient outcomes and support.

Tactile Systems (TCMD) reports strong Q2 earnings and growth outlook

Tactile Systems (TCMD) showcased robust financial performance, operational efficiency gains, and strategic talent additions in Q2 2023.
While facing challenges like AffloVest sales slowdown, the company raised revenue guidance and expects strong profitability with adjusted EBITDA of $25-27 million for 2023.
Opportunities lie in the head and neck trial's potential impact on revenue, Kylee app engagement benefits, and strategic priorities driving growth.

Tactile Systems reports revenue growth and strategic initiatives progress

Tactile Systems' Q3 performance showed revenue growth and improved profitability, supported by strategic initiatives and margin improvement efforts.
While facing challenges in AffloVest sales and patient acquisition, the company is optimistic about opportunities in therapy expansion and operational enhancements.
Consistent price increases and focus on technology-driven efficiencies are key strengths, with a focus on achieving ambitious 2025 targets.
Overall, Tactile Systems is navigating challenges while capitalizing on opportunities for growth and operational optimization.

Tactile Systems posts robust Q4 results, eyes growth opportunities

Tactile Systems delivered strong financial performance in Q4 2023, with revenue and net income growth. The company provided optimistic revenue guidance for 2024 and outlined strategic priorities for driving growth and enhancing customer experience. Challenges include anticipated headwinds and limited margin gains in the short term.

Tactile Systems reports Q1 growth, doubles EBITDA, eyes tech expansion

Tactile Systems reported solid financial performance with revenue growth and doubled adjusted EBITDA.
The company is strategically investing in tech advancements, new products, and expanding sales channels.
Challenges include addressing declining airway clearance revenues and optimizing sales rep impact.
Opportunities lie in expanding clinical trials, enhancing product user experience, and leveraging tech investments.

Tactile Systems (TCMD) reports robust Q2 earnings amidst Medicare challenges

Tactile Systems' Q2 2024 performance reflects solid financial growth and strategic initiatives. While facing challenges from Medicare documentation requirements, the company is focused on adapting to regulatory changes. Opportunities lie in capital allocation strategies, technology advancements, and market expansion efforts.

Tactile Systems reports Q3 growth, faces documentation challenges and opportunities

Tactile Systems delivered solid Q3 performance with revenue growth and improved EBITDA, despite challenges in sales productivity.
The company's strategic strengths lie in strong market demand, product innovation, and a shareholder-friendly capital allocation strategy.
Navigating challenges related to regulatory changes and operational efficiency while capitalizing on growth opportunities will be key for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

MINNEAPOLIS, March 30, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2023 financial results will be released after the market opens on Monday, May 8.

Tactile Medical to Release First Quarter of Fiscal Year 2023 Financial Results on May 8, 2023

MINNEAPOLIS, March 14, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Elaine Birkemeyer to the position of Chief Financial Officer, effective March 20, 2023. Ms. Birkemeyer will succeed Brent Moen, who is retiring.

Tactile Medical Appoints Elaine Birkemeyer as Chief Financial Officer

MINNEAPOLIS, March 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the following upcoming investor conferences:

Tactile Medical to Present at Two Upcoming Conferences in March

MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $13.00 per share. The gross proceeds to Tactile Medical from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $32.5 million. Additionally, Tactile Medical has granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Tactile Medical anticipates using the net proceeds from the offering to (i) expand commercial activities, (ii) fund milestone payments, (iii) support new product development, (iv) broaden reimbursement coverage for Tactile Medical's patient population, (v) fund potential acquisitions and (vi) provide working capital and for other general corporate purposes, which may include general debt reduction. All of the shares are being offered by Tactile Medical, and the offering is expected to close on or about February 28, 2023, subject to customary closing conditions.

Tactile Systems Technology, Inc. Announces Pricing of $32.5 Million Public Offering of Common Stock

MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Tactile Medical intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock to be sold in the proposed offering will be sold by Tactile Medical. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual terms of the offering.

Tactile Systems Technology, Inc. Announces Proposed Public Offering of Common Stock

Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q4 2022 Earnings Conference Call February 21, 2023 8:00 AM ET Company Participants Daniel Reuvers - President and Chief Executive Officer Brent Moen - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Margaret Kaczor - William Blair Ryan Zimmerman - BTIG Suraj Kalia - Oppenheimer Operator Welcome, ladies and gentlemen to the Fourth Quarter and Fiscal Year 2022 Earnings Conference Call for Tactile Medical. At this time, all participants have been placed in a listen-only mode.

Tactile Systems Technology, Inc. (TCMD) Q4 2022 Earnings Call Transcript

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 107.14% and 4.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Q4 Earnings and Revenues Top Estimates

Fourth Quarter Revenue Increased 20% Year-Over-Year; Full Year Revenue Increased 19% Year-Over-Year Fourth Quarter Revenue Increased 20% Year-Over-Year; Full Year Revenue Increased 19% Year-Over-Year

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results; Introduces Full Year 2023 Outlook

MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Brent Moen has communicated his intention to retire as Chief Financial Officer in 2023.

Tactile Systems Technology, Inc. Announces Chief Financial Officer to Retire in 2023

MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Tuesday, February 21st.

Tactile Medical to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 21, 2022

MINNEAPOLIS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Carmen Volkart to the Company's Board of Directors (“Board”), effective January 5, 2023.

Tactile Medical Appoints Carmen Volkart to Board of Directors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Tactile Systems Technology (TCMD) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Despite Fast-paced Momentum, Tactile Systems Technology (TCMD) Is Still a Bargain Stock

Neovasc

Veracyte

Here we discuss three medical instruments stocks - TCMD, VCYT and NVCN - that have started to recover in the past few months after declining for the major part of 2022.

3 Medical Instruments Stocks on Recovery Path After Dismal 2022

Tactile Systems Technology, Inc. continues to grow its top line hastily each quarter, which demonstrates it is capturing additional market share. Airway clearance segment growth was good, yet we are constructive on its lymphedema segment.

Tactile Systems: Lymphedema, Airway Clearance Markets Attractive

Tactile Systems Technology (TCMD) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Tactile Systems Technology (TCMD)

The consensus price target hints at a 168.2% upside potential for Tactile Systems Technology (TCMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Tactile Systems Technology (TCMD) Could Surge 168%: Read This Before Placing a Bet

iRadimed

Shockwave Medical

Here we discuss ShockWave Medical (SWAV), iRadimed (IRMD) and Tactile Systems Technology (TCMD), which have the potential to outperform their industry going forward.

3 Medical Instruments Stocks With Potential to Outperform

MINNEAPOLIS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that management will participate in the Piper Sandler 34th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY. Management will participate in a fireside chat on Wednesday, November 30th at 1:30 p.m. Eastern Time.

Tactile Medical to Participate in the Piper Sandler 34th Annual Healthcare Conference

MINNEAPOLIS, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical” or the “Company”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that it has entered into a Memorandum of Understanding (“MOU”) to settle the previously disclosed securities class action lawsuit pending in the United States District Court for the District of Minnesota titled Mart v. Tactile Systems Technology, Inc. et al.   The Company does not expect to fund any portion of the cash payments made in connection with the settlement.

Tactile Medical Reaches Agreement to Settle Securities Class Action Lawsuit

The mean of analysts' price targets for Tactile Systems Technology (TCMD) points to an 187.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Tactile Systems Technology (TCMD) Could Rally 188%: Here's is How to Trade

Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Dan Reuvers - President and Chief Executive Officer Brent Moen - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Margaret Kaczor - William Blair Suraj Kalia - Oppenheimer Operator Welcome, ladies and gentlemen to the Third Quarter of Fiscal Year 2022 Earnings Conference Call for Tactile Medical. [Operator Instructions] At the end of the company's prepared remarks, we will conduct a question-and-answer session.

Tactile Systems Technology, Inc. (TCMD) Q3 2022 Earnings Call Transcript

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 200% and 8.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Tops Q3 Earnings and Revenue Estimates

Third Quarter Revenue Increased 24% Year-Over-Year; First Nine Months Revenue Increased 18% Year-Over-Year Third Quarter Revenue Increased 24% Year-Over-Year; First Nine Months Revenue Increased 18% Year-Over-Year

Tactile Systems Technology, Inc. Reports Third Quarter 2022 Financial Results; Raises Full Year 2022 Outlook

Tactile Systems Technology (TCMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Tactile Systems Technology (TCMD) Moves 6.6% Higher: Will This Strength Last?

MINNEAPOLIS, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that third quarter of fiscal year 2022 financial results will be released after the market closes on Monday, November 7th.

News for Tactile Systems Stock (TCMD)